MEDNAX

Pediatrix Medical Group, Inc. engages in the provision of physician services. It includes newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care. The company was founded by Roger J. Medel in 1979 and is headquartered in Sunrise, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

MEDNAX reports stable Q4 performance, eyes in-network growth opportunities

MEDNAX's Q4 call highlighted stable performance, strategic focus on core areas, and challenges from R1 transition and labor inflation. Opportunities in payer relationships, acquisitions, and organic growth are key for future success.

MEDNAX (MD) reports solid Q1 performance, eyes growth opportunities

MEDNAX's Q1 2023 performance showcased stability in patient volumes, pricing strength, and effective cost management. The company's focus on revenue cycle management and debt reduction yielded positive outcomes. Addressing challenges and seizing growth opportunities will be key for sustained success.

MEDNAX (MD) reports strong Q2 performance and eyes growth opportunities

MEDNAX (MD) delivers a solid performance in Q2 2023 with stable patient volumes, strong pricing, and cost efficiencies. The company's focus on improving AR collections, expanding clinics, and potential acquisitions positions it well for future growth.

MEDNAX reports Q3 earnings below forecast, revises full-year outlook

MEDNAX acknowledges disappointing Q3 results, plans structural changes to address challenges, and revises full-year adjusted EBITDA outlook. Despite facing operational challenges, the company shows strength in managing cash and negotiating subsidies with hospital partners.

MEDNAX meets Q4 expectations, eyes stable growth and cost efficiencies

MEDNAX's Q4 performance met expectations, with a focus on stabilizing margins and narrowing financial performance range. The company is poised for stable revenue growth in 2024, with opportunities to deploy capital for acquisitions and improve cost efficiencies. Challenges include stabilizing margins and addressing modest revenue growth expectations.

MEDNAX reports strong Q1 results, accelerates restructuring for growth

MEDNAX's Q1 performance reflects positive revenue growth and operational efficiency initiatives. While facing challenges in communicating practice exits and financial impacts, the company is well-positioned to capitalize on growth opportunities in core services. By focusing on restructuring and maintaining financial discipline, MEDNAX aims to drive continued progress throughout 2024.

MEDNAX surpasses Q2 expectations, focuses on strategic realignment for growth

MEDNAX's Q2 performance exceeded expectations with revenue growth and cost efficiencies driving results.
While facing challenges from restructuring, the company aims to capitalize on opportunities for margin improvement.
Maintaining financial outlook, appointing new leadership, and strategic shifts position MEDNAX for future growth.
Overall, MEDNAX's focus on operational enhancements and strategic realignment bode well for its financial health.

MEDNAX surpasses Q3 expectations with strategic initiatives driving growth

MEDNAX delivered strong Q3 performance with revenue growth, stable patient volumes, and successful operational transitions.
Strategic initiatives like portfolio restructuring and improved liquidity position highlight the company's focus on long-term sustainability.
While challenges like executing restructuring plans and managing liquidity exist, opportunities for growth and value creation are also present.
Overall, MEDNAX's financial outlook remains positive, supported by operational efficiency and prudent financial management.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

EL SEGUNDO, Calif.--(BUSINESS WIRE)-- #PracticeNotCompany--Radiology Partners (RP), the leading radiology practice in the U.S., today announced the completion of its acquisition of MEDNAX Radiology Solutions, a division of MEDNAX, Inc. (NYSE: MD), in a transaction valued at approximately $885 million. Following all necessary regulatory approvals—including the Federal Trade Commission's (FTC) Hart-Scott Rodino (HSR) antitrust review process and other customary closing conditions—the acquisition closed and became effe

Radiology Partners Completes Acquisition of MEDNAX Radiology Solutions

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--MEDNAX Completes Sale of MEDNAX Radiology Solutions to Radiology Partners

MEDNAX Completes Sale of MEDNAX Radiology Solutions to Radiology Partners

Mednax (MD) reported earnings 30 days ago. What's next for the stock?

Mednax (MD) Up 60.5% Since Last Earnings Report: Can It Continue?

MEDNAX's (MD) third-quarter results reflect muted revenues and high costs, partly offset by lower interest expense.

MEDNAX's (MD) Q3 Earnings Meet Estimates, Revenues Miss

MEDNAX, Inc. (MD) CEO Mark Ordan on Q3 2020 Results - Earnings Call Transcript

Shares of Mednax (NYSE:MD) rose 5.3% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell 59.34% year over year to $0.37, which missed the estimate of $0.40.

Recap: Mednax Q3 Earnings

Mednax (MD) delivered earnings and revenue surprises of -7.50% and -13.87%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Mednax (MD) Lags Q3 Earnings and Revenue Estimates

Mednax (MD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Mednax (MD) Q3 Earnings Expected to Decline

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--MEDNAX 2020 Third Quarter Conference Call/Webcast Scheduled for Friday, November 6, 2020

MEDNAX 2020 Third Quarter Conference Call/Webcast Scheduled for Friday, November 6, 2020

Riding on restructuring as well as cost-cutting initiatives, MEDNAX (MD) holds potential to reap benefits for investors.

Why Should You Retain MEDNAX (MD) in Your Portfolio Now?

NEW YORK, Sept. 15, 2020 /PRNewswire/ -- DLA Piper represented MEDNAX, Inc.

DLA Piper advises MEDNAX in its US$885 million sale of MEDNAX Radiology Solutions to Radiology Partners

MEDNAX (MD) reaches an agreement with Radiology Partners to sell its MEDNAX Radiology Solutions, which will lower its debt load and restructure its business.

MEDNAX Divests Radiology Business to Focus on Core Operations

MEDNAX (MD) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

MEDNAX (MD) Catches Eye: Stock Jumps 5.4%

Mednax Inc. MD, +0.73% said Thursday it has reached an agreement to sell its radiology business to physician-owned Radiology Partners for $885 million in cash.

Mednax to sell radiology business to doctor-owned Radiology Partners for $885 million in cash

EL SEGUNDO, Calif.--(BUSINESS WIRE)--Radiology Partners (RP), the leading radiology practice in the U.S.

Radiology Partners Signs Definitive Agreement to Acquire MEDNAX Radiology Solutions

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--MEDNAX Announces Agreement to Sell MEDNAX Radiology Solutions to Radiology Partners

MEDNAX Announces Agreement to Sell MEDNAX Radiology Solutions to Radiology Partners

Why Is Mednax (MD) Down 5.3% Since Last Earnings Report?

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--MEDNAX Announces Financial Leadership Transition - C.

MEDNAX Announces Financial Leadership Transition

MEDNAX, Inc. (MD) CEO Mark Ordan on Q2 2020 Results - Earnings Call Transcript

MEDNAX's (MD) Q2 results reflect lower expenses, offset by soft revenues.

MEDNAX's (MD) Q2 Earnings Surpass Estimates, Decline Y/Y

Shares of Mednax (NYSE:MD) were flat in pre-market trading after the company reported Q2 results.

Recap: Mednax Q2 Earnings

Mednax (MD) delivered earnings and revenue surprises of 113.33% and -13.83%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Mednax (MD) Q2 Earnings Top Estimates

Analysts Estimate Mednax (MD) to Report a Decline in Earnings: What to Look Out for

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--MEDNAX 2020 Second Quarter Conference Call/Webcast Scheduled for Thursday, July 30, 2020

MEDNAX 2020 Second Quarter Conference Call/Webcast Scheduled for Thursday, July 30, 2020

Pressure from the COVID-19 impact on global economy and lack of solvency make MEDNAX (MD) an unattractive bet.

News for MEDNAX Stock (MD)